Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

ams; our planned Phase 2 clinical studies and the ability of those studies to successfully evaluate HspE7 as a potential treatment for CIN 1 and CIN 2/3; the structure and location of our planned Phase 2 trials; completion of the second protocol for CIN 1; potential uses for Poly-ICR; our ability to advance Poly-ICR resulting in revenue generation and internal development; the ability of Poly-ICR to provide us with near-term revenue opportunity; the development of Poly-ICR for treatment of GW and actinic keratosis; completion of development activities and the filing of an IND application in connection with Poly-ICR; finalizing manufacturing and formulation protocols and filing an IND in connection with Hsp 6/11; execution of our corporate restructuring as planned; our ability to retain key personnel; and our plan to expand corporate development efforts and the potential results of such efforts.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that our planned corporate restructuring will not have the anticipated affect; that we will not succeed in forming strategic alliances and, if we do, the possibility that such alliances will not allow us to realize the greatest value for our programs; that we will not commence Phase 2 clinical studies as planned and, if we do, that such studies will not support the use of HspE7 as a treatment for CIN 1 or CIN 2/3; that we will not complete the second protocol for the CIN 1 indication; that Poly-IRC will not be useful as a broad immune stimulatory agent or vaccine adjuvant; that we will not be able to advance Poly-ICR to generate revenue or for internal development; that Poly-ICR will not provide us with near-term reve
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... full year 2014 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:3/5/2015)... Va. , March 5, 2015   HX360 ... as semi-finalists in the HX360 Innovation Challenge ... entries, will compete to be chosen as one of ... panel of senior health system executives and venture capitalists ... HX360 Innovation Challenge takes place at the 2015 HIMSS ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery made possible ... improvement in histological quality provided the detail necessary ... daughter cells. , After processing with Ultralight Histology’s ... 1000-1600x using light microscopy. Phylogenetic and histologic ... cells displayed predominant binary features --- one nucleus ...
(Date:3/5/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ... Biotech Outlook 2015: New Therapy Ventures Pave the Way ... All biotech companies - Gilead (GILD), Amgen (AMGN), ... have given a positive return and hence increased the ... to select therapy/niche indication where the high treatment cost ...
Breaking Biology Technology:BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3
... 20 LUMEDX Corporation, a leading,provider of ... the latest version of its real-time patient ... of patients, physicians, staff, rooms with drag ... resource utilization and,substantial ROI., A free ...
... a list of the 25 new and most pressing issues ... 2050. As well as highlighting areas where research effort should ... us foresee issues that have taken scientists and policy makers ... response to genetically modified crops. , The list, published online ...
... Mass., March 19 Biopure,Corporation (Nasdaq: ... Kingdom,s,Medicines and Healthcare products Regulatory Agency (MHRA) ... manufacturing facility. The,inspection report contained no "Critical" ... manufacturing practices. The MHRA report identified,shortcomings characterized ...
Cached Biology Technology:LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems 2Biopure Completes U.K. Regulatory Agency Inspection 2
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting its ... and has launched a new marketing campaign to solidify ... (CLO).  The new campaign focuses on First ... and shipments. The first headline in the ... Marken,s priorities with its client,s priorities. Marken recognizes the ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... first comprehensive genetic study of humpback whale populations in the ... the same time a proposal to designate North Pacific humpbacks ... the Endangered Species Act. Results of the study are ... Progress Series . It was supported by the National ...
... dramatic subpolar fjords of Antarctica, researchers from the ... unexpected abundance and diversity at the seafloor. During ... time studied the seafloor communities of glacier dominated ... undergoing very rapid climate warming. The ...
... a way to stabilize hemoglobin, the oxygen carrier protein ... the development of stable vaccines and affordable artificial blood ... polymer poly(acrylic acid) around hemoglobin, protecting it from the ... maintain its biological function and structural integrity. In ...
Cached Biology News:New study identifies 5 distinct humpback whale populations in North Pacific 2New study identifies 5 distinct humpback whale populations in North Pacific 3Antarctic fjords are climate-sensitive hotspots of diversity in a rapidly warming region 2Antarctic fjords are climate-sensitive hotspots of diversity in a rapidly warming region 3New method for stabilizing hemoglobin could lead to stable vaccines, artificial blood 2New method for stabilizing hemoglobin could lead to stable vaccines, artificial blood 3
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... 1575 immunowash microplate washer 100-240 V, is ... flat-, U-, or V-bottom wells. The immunowash ... vertical needle positions to an accuracy of ... and overflow washing. It can store up ...
... MULTI-FUN Incubator is a compact benchtop ... a microprocessor controller with a large ... and agitation speed. Air circulation inside ... incubator. Temperature can be easily calibrated ...
... The CERTOMAT RM is specifically designed as ... densities. The new variable mass compensation allows ... conditions yielding better aeration and, therefore, faster ... orbital shaker is ideal when high reproducibility ...
Biology Products: